Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model
Open Access
- 1 January 2020
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 9 (1) , 1757360
Abstract
Recent advances in novel immune strategies, particularly chimeric antigen receptor (CAR)-bearing T-cells, have shown limited efficacy against glioblastoma (GBM) in clinical trials. We currently have an incomplete understanding of how these emerging therapies integrate with the current standard of care, specifically radiation therapy (RT). Additionally, there is an insufficient number of preclinical studies monitoring these therapies with high spatiotemporal resolution. To address these limitations, we report the first longitudinal fluorescence-based intravital microscopy imaging of CAR T-cells within an orthotopic GBM preclinical model to illustrate the necessity of RT for complete therapeutic response. Additionally, we detail the first usage of murine-derived CAR T-cells targeting the disialoganglioside GD2 in an immunocompetent tumor model. Cell culture assays demonstrated substantial GD2 CAR T-cell-mediated killing of murine GBM cell lines SB28 and GL26 induced to overexpress GD2. Complete antitumor response in advanced syngeneic orthotopic models of GBM was achieved only when a single intravenous dose of GD2 CAR T-cells was following either sub-lethal whole-body irradiation or focal RT. Intravital microscopy imaging successfully visualized CAR T-cell homing and T-cell mediated apoptosis of tumor cells in real-time within the tumor stroma. Findings indicate that RT allows for rapid CAR T-cell extravasation from the vasculature and expansion within the tumor microenvironment, leading to a more robust and lasting immunologic response. These exciting results highlight potential opportunities to improve intravenous adoptive T-cell administration in the treatment of GBM through concurrent RT. Additionally, they emphasize the need for advancements in immunotherapeutic homing to and extravasation through the tumor microenvironment.Keywords
Funding Information
- Ben and Catherine Ivy Foundation (UACDV)
- Canary Foundation (UABTN)
This publication has 44 references indexed in Scilit:
- A safe and potent anti-CD19 CAR T cell therapyNature Medicine, 2019
- Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysisJournal of Neuro-Oncology, 2018
- Expert consensus on re-irradiation for recurrent gliomaRadiation Oncology, 2017
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escapeJournal of Clinical Investigation, 2016
- T cell exclusion, immune privilege, and the tumor microenvironmentScience, 2015
- Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastomaScience Translational Medicine, 2015
- Enhancement of T Cell Responses as a Result of Synergy between Lower Doses of Radiation and T Cell StimulationThe Journal of Immunology, 2014
- Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor–Modified T CellsClinical Cancer Research, 2012
- Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumorsJournal of Clinical Investigation, 2012
- Real-time imaging reveals the single steps of brain metastasis formationNature Medicine, 2009